NSE: IPCALAB | BSE: 524494

Mid-range Performer

Download real time

1444.20 -64.00 (-4.24%)

52W high on Mar 17, 2026

83,219 NSE+BSE Volume

NSE 02 Apr, 2026 10:52 AM (IST)

36,640

Market Cap

High in industry

Beta 1Year

Very Low volatility

Ipca Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for IPCALAB, BSE:524494 Ipca Laboratories Ltd.

Search Inside the pdf :

Ipca Laboratories Ltd.

17 Mar 2026

1444.20

-4.24%

Growth visibility improving in DF and exports

Buy: Ipca Laboratories Ltd.

Target

Motilal Oswal

IPCA is taking multiple initiatives for its domestic formulation (DF) segment, such as cardiology portfolio restructuring, Zerodol franchise strengthening, RA focus within pain management, and entry into high-end cosmo-dermatology, to boost its growth prospects.

Ipca Laboratories Ltd.'s price crossed below 50Day SMA today

Ipca Laboratories Ltd.

06 Mar 2026

1444.20

-4.24%

Ipca Laboratories (IPCA IN) Management Meet Update Steady growth visibility BUY

Buy: Ipca Laboratories Ltd.

Target

Prabhudas Lilladhar

We interacted with the management of IPCA Laboratories (IPCA) to assess its medium-term growth trajectory. The company is prioritizing disciplined execution over aggressive diversification, with a clear focus on strengthening its core businesses while building growth levers. Domestic formulations and branded generics which now contribute 45% of revenues and ~70% of EBITDA, continued to outperform market and grow at healthy levels. We expect IPCA to deliver revenue growth ex Unichem at +11% over FY26-28E with normalization in export generic and API business. This will aid operating...

Ipca Laboratories Ltd. has an average target of 1806.67 from 3 brokers.

Ipca Laboratories Ltd.

17 Feb 2026

1444.20

-4.24%

Ipca Laboratories (IPCA IN) Q3FY26 Result Update Margin surprise BUY

Buy: Ipca Laboratories Ltd.

Recommendation Target

Prabhudas Lilladhar

Ipca reported strong EBITDA of Rs5.3bn (up 19% YoY) which was 10% above our estimates. Company has witnessed 400bps GMs expansion ex Unichme for 9MFY26 which should sustain given product mix and softer raw material prices. Export API business witnessed recovery in 9MFY26 with 26% YoY growth. Domestic formulation business, which now contributes 40% of revenues and ~55% of EBITDA, continued to outperform and grow at healthy levels. We believe 1) recovery in API segment 2) higher margins ex Unichem 3) steady...

Number of FII/FPI investors decreased from 254 to 248 in Dec 2025 qtr

Ipca Laboratories Ltd.

17 Feb 2026

1444.20

-4.24%

Ipca Laboratories

Buy: Ipca Laboratories Ltd.

Target

ICICI Direct

Revenue break-up Q3FY26 Formulations: 64% (domestic: 41%, export: 22% - export generic: 11%, export institutional: 2%, export branded: 9%), APIs: 13% (export API: 10%, domestic API: 3%), subsidiaries: 23%...

Ipca Laboratories Ltd. is trading above its 200 day SMA of 1418.5

Ipca Laboratories Ltd.

16 Feb 2026

1444.20

-4.24%

Branded generics drive earnings

Buy: Ipca Laboratories Ltd.

Target

Motilal Oswal

Ipca Laboratories (IPCA) reported in-line revenue and better-than-expected EBITDA/PAT (10%/12% beat) in 3QFY26, aided by product mix, favorable currency and a lower tax rate.

Motilal Oswal increased Buy price target of Ipca Laboratories Ltd. to 1820.0 on 17 Mar, 2026.

Ipca Laboratories Ltd.

17 Nov 2025

1444.20

-4.24%

Ipca Laboratories

Buy: Ipca Laboratories Ltd.

Recommendation Target

ICICI Direct

Q2FY26- Revenues growth a little subdued but margins strongRevenues grew ~9% YoY to 2556.5 crore driven by both domestic formulations and API exports. Domestic formulations grew 8% YoY to 1019 crore, driven by strong traction in pain management but also had some impact on account of GST rate rationalization. Export APIs grew ~45% to 221 crore. Under exports formulations - Branded exports grew ~2% to 145 crore, Institutional exports de-grew 29% YoY to 79.7 crore and generic exports de-grew 6% YoY to 268 crore. EBITDA grew 23.4% YoY to 545 crore while EBITDA margins grew by 257 bps to 21.3% aided...

Ipca Laboratories Ltd. has an average target of 1806.67 from 3 brokers.

Ipca Laboratories Ltd.

13 Nov 2025

1444.20

-4.24%

Beat on estimates; DF/API drive earnings

Buy: Ipca Laboratories Ltd.

Target

Motilal Oswal

Ipca Laboratories (IPCA) delivered slightly better-than-expected revenue in 2QFY26, while EBITDA/PAT beat our estimates by 18%/22%.

Ipca Laboratories Ltd.'s price crossed below 50Day SMA today

Ipca Laboratories Ltd.

13 Aug 2025

1444.20

-4.24%

Ipca Laboratories (IPCA IN) Q1FY26 Result Update EBITDA...

Accumulate: Ipca Laboratories Ltd.

Prabhudas Lilladhar

was weak with 4.3% OPM; impacted by certain one offs and price erosion in certain products. Mgmt. reiterated its FY26 guidance of 9-10% revenue growth however 75bps margin expansion vs 100 bps earlier. Our FY26E and FY27E EPS...

Ipca Laboratories Ltd. is trading above its 200 day SMA of 1418.5

Ipca Laboratories Ltd.

31 May 2025

1444.20

-4.24%

Ipca Laboratories (IPCA IN) Q4FY25 Result Update Muted...

Accumulate: Ipca Laboratories Ltd.

Target

Prabhudas Lilladhar

Ipca Labs (IPCA) reported EBITDA of Rs4.1bn (up 35% YoY), was in line with our estimates. However, mgmt. FY26 guidance of 8-10% revenue growth was below our expectations (12-13%). Resultant, our FY26E and FY27E EPS stands reduced by 4-8%. API and generic business growth were muted in FY25; recovery will be gradual. Domestic formulation business, which now contributes 40% of revenues and ~55% of EBITDA, continued to outperform and grow at healthy levels. Turnaround in Unichem remains on track with...